A weapon to fight against pervasive Omicron: systematic actions transiting to pre-COVID normal.

The Coronavirus Disease-2019 (COVID-19) pandemic is not just a health crisis but also a social crisis. Confronted with the resurgence of variants with massive infections, the triggered activities from personal needs may promote the spread, which should be considered in risk management. Meanwhile, it is important to ensure that the policy responses on citizen life to a lower level. In the face of Omicron mutations, we need to sum up the control experience accumulated, adapting strategies in the dynamic coevolution process while balancing life resumption and pandemic control, to meet challenges of future crises. We collected 46 cases occurring between 2021 and 2022, mainly from China, but also including five relevant cases from other countries around the world. Based on case studies, we combine micro-view individual needs/behaviors with macro-view management measures linking Maslow's hierarchy of needs with the transmission chain of Omicron clusters. The proposed loophole chain could help identify both individual and management loopholes in the spread of the virus. The systematic actions that were taken have effectively combated these ubiquitous vulnerabilities at lower costs and lesser time. In the dynamic coevolution process, the Chinese government has made effective and more socially acceptable prevention policies while meeting the divergent needs of the entire society at the minimum costs. Systematic actions do help maintain the balance between individuals' satisfaction and pandemic containment. This implies that risk management policies should reasonably consider individual needs and improve the cooperation of various stakeholders with targeted flexible measures, securing both public health and life resumption.

A novel dimeric thymosin beta 4 with enhanced activities accelerates the rate of wound healing.

OBJECTIVE: Thymosin beta 4 (Tß4) is a peptide with 43 amino acids that is critical for repair and remodeling tissues on the skin, eye, heart, and neural system following injury. To fully realize its utility as a treatment for disease caused by injury, the authors constructed a cost-effective novel Tß4 dimer and demonstrated that it was better able to accelerate tissue repair than native Tß4. METHODS: A prokaryotic vector harboring two complete Tß4 genes with a short linker was constructed and expressed in Escherichia coli. A pilot-scale fermentation (10 L) was performed to produce engineered bacteria and the Tß4 dimer was purified by one-step hydrophobic interaction chromatography. The activities of the Tß4 dimer to promote endothelial cell proliferation, migration, and sprouting were assessed by tetramethylbenzidine (methylthiazol tetrazolium), trans-well, scratch, and tube formation assays. The ability to accelerate dermal healing was assessed on rats. RESULTS: After fermentation, the Tß4 dimer accounted for about 30% of all the bacteria proteins. The purity of the Tß4 dimer reached 98% after hydrophobic interaction chromatography purification. An average of 562.4 mg/L Tß4 dimer was acquired using a 10 L fermenter. In each assay, the dimeric Tß4 exhibited enhanced activities compared with native Tß4. Notably, the ability of the dimeric Tß4 to promote cell migration was almost two times higher than that of Tß4. The rate of dermal healing in the dimeric Tß4-treated rats was approximately 1 day faster than with native Tß4-treated rats. CONCLUSION: The dimeric Tß4 exhibited enhanced activity on wound healing than native Tß4, and the purification process was simple and cost-effective. This data could be of significant benefit for the high pain and morbidity associated with chronic wounds disease. A better strategy to develop Tß4 as a treatment for other diseases caused by injuries such as heart attack, neurotrophic keratitis, and multiple sclerosis was also described.